Other variables, including disease prevalence, LDH levels, and PD-L1 expression, failed to reach statistical significance in impacting PFS, likely attributable to the limited statistical power of the study (see Figure 3 ).
← all excerpts
Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study.
1
—
—